266. 家族性地中海熱 [臨床試験数:16,薬物数:14(DrugBank:6),標的遺伝子数:14,標的パスウェイ数:52]
Searched query = "Familial mediterranean fever"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000032557 | 2018/09/01 | 5 November 2019 | An open-label continuation trial of tocilizumab for familial Mediterranean fever (FMF) with colchicine ineffective or intolerance | An open-label continuation trial of tocilizumab for familial Mediterranean fever (FMF) with colchicine ineffective or intolerance - An open-label continuation trial of tocilizumab for familial Mediterranean fever | familial Mediterranean fever | Tocilizumab | Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences | Recruiting | 12years-old | 76years-old | Male and Female | 24 | Not selected | Japan | |
2 | NCT03563300 | September 1, 2018 | 29 April 2019 | Gluten-related Disorders in Familial Mediterranean Fever Patients | Gluten-related Disorders in Patients Affected With Familial Mediterranean Fever | Not-celiac Wheat Sensitivity (NCWS);Familial Mediterranean Fever (FMF) | Other: Wheat flour;Other: Placebo Comparator | University of Palermo | Not recruiting | 18 Years | 65 Years | All | 8 | N/A | Italy | |
3 | NCT03446209 | April 23, 2018 | 29 April 2019 | Tocilizumab for the Treatment of Familial Mediterranean Fever | Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study | Familial Mediterranean Fever | Drug: 0.9% physiological saline;Drug: Tocilizumab Infusion RoAcemtra (EU) | University Hospital Tuebingen | Recruiting | 18 Years | 64 Years | All | 30 | Phase 2 | Germany | |
4 | JPRN-UMIN000028010 | 2018/03/01 | 22 July 2019 | Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever | Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever - Clinical trial of Tocilizumab for colchicine-resistant familial Mediterranean fever | familial Mediterranean fever | Tocilizumab Placebo | Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences | Not Recruiting | 12years-old | Not applicable | Male and Female | 24 | Not selected | Japan | |
5 | EUCTR2016-004505-13-DE | 27/11/2017 | 30 April 2018 | Tocilizumab for the Treatment of Familial Mediterranean Fever | Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE - Tocilizumab for the Treatment of Familial Mediterranean Fever | Adult patients with Familial Mediterranean Fever, who have active disease MedDRA version: 20.0 Level: PT Classification code 10016207 Term: Familial mediterranean fever System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: RoActemra® 20mg/ml Konzentrat CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 8- Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use | University Hospital Tuebingen | Authorised | Female: yes Male: yes | 30 | Phase 2 | Germany | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT03210610 | October 19, 2017 | 11 June 2018 | Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) Patients | Measurement of Colchicine Levels in the Serum of FMF Patients | FMF;Colchicine Resistance;Colchicine Toxicity | Diagnostic Test: colchicine level measurement | Sheba Medical Center | Recruiting | 18 Years | N/A | All | 80 | Phase 4 | Israel | |
7 | EUCTR2017-001678-40-Outside-EU/EEA | 22 May 2017 | An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes | An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes | Three disease of periodic fever syndromes, TNF receptor Associated Periodic Syndrome (TRAPS), Hyper IgDSyndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF MedDRA version: 20.0 Level: SOC Classification code 10010331 Term: Congenital, familial and genetic disorders System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Ilaris Pharmaceutical Form: Solution for injection INN or Proposed INN: CANAKINUMAB CAS Number: 914613-48-2 Current Sponsor code: ACZ885 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 4- | Novartis pharma AG | Not Available | Female: yes Male: yes | 4 | Phase 3 | Japan | ||||
8 | NCT02175589 | June 2014 | 19 February 2015 | Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation | Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation | Familial Mediterranean Fever | Other: Colchicine Cessation | Rambam Health Care Campus | Schneider Children's Hospital | Recruiting | 2 Years | 18 Years | Both | 80 | Phase 2 | Israel |
9 | NCT02021084 | December 2013 | 17 October 2016 | The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever. | Familial Mediterranean Fever (FMF ) | Dietary Supplement: probiotic;Dietary Supplement: Placebo | Rambam Health Care Campus | Not recruiting | 5 Years | 18 Years | Both | 0 | N/A | |||
10 | NCT01705756 | November 2012 | 16 December 2017 | Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever | A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever | Familial Mediterranean Fever | Drug: Kineret | Sheba Medical Center | Not recruiting | 18 Years | 65 Years | All | 25 | Phase 3 | Israel | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT02602028 | April 2011 | 23 November 2015 | The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF | The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial | Familial Mediterranean Fever | Drug: colchicine | Gulhane Military Medical Academy | Not recruiting | 5 Years | 16 Years | Both | 79 | Phase 4 | Turkey | |
12 | NCT01148797 | December 2010 | 28 November 2016 | Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF) | A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever | Colchicine Resistant/Intolerant Familial Mediterranean Fever | Drug: Canakinumab | Novartis Pharmaceuticals | Not recruiting | 4 Years | 20 Years | Both | 15 | Phase 2 | Israel | |
13 | NCT01075906 | August 2010 | 19 February 2015 | Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients | An Open-label, Parallel-group, Multiple-Dose, Pharmacokinetic and Safety Study of Colchicine Pediatric Formulation in Pediatric and Adult Patients With FMF | Familial Mediterranean Fever | Drug: colchicine sprinkle capsules | Mutual Pharmaceutical Company, Inc. | Not recruiting | 2 Years | 65 Years | Both | 75 | Phase 1 | United States;Armenia;Israel;Turkey | |
14 | NCT01088880 | April 2010 | 19 February 2015 | Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever | An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever | Familial Mediterranean Fever | Drug: Canakinumab | Novartis Pharmaceuticals | Not recruiting | 12 Years | 75 Years | Both | 10 | Phase 2 | Turkey | |
15 | NCT00582907 | August 2008 | 19 October 2017 | Rilonacept for Treatment of Familial Mediterranean Fever (FMF) | Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF) | Familial Mediterranean Fever | Drug: Rilonacept;Drug: Placebo | The Cleveland Clinic | Not recruiting | 4 Years | N/A | All | 14 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
16 | NCT00094900 | October 2004 | 19 October 2017 | Interleukin-1 Trap to Treat Autoinflammatory Diseases | Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis | Inflammation;Familial Mediterranean Fever;Still's Disease, Adult-Onset | Drug: IL-1 Trap | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Not recruiting | 18 Years | N/A | All | 11 | Phase 2 | United States |